Regencell Bioscience Holdings Ltd
RGC- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001829667
No open-market purchases or sales by Regencell Bioscience Holdings Ltd insiders were filed in the last 90 days; 35 institutions reported holding it in 13F filings for Q2 2026, worth $8.56M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 35
- 13F valueReported value at the end of Q2 2026
- $8.56M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RGC, Q2 2026
No superinvestor reported holding RGC at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Regencell Bioscience Holdings Ltd insiders from Form 4, newest first.
No open-market purchases or sales by Regencell Bioscience Holdings Ltd insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Regencell Bioscience Holdings Ltd at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 422,011 | $2.57M | 0.00% | +6,442+1.6% | Added |
| Alyeska Investment Group, L.P. | 416,261 | $2.54M | 0.01% | +416,261 | New |
| Legal & General Group Plc | 128,000 | $779.0K | 0.00% | +118,097+1,192.5% | Added |
| Jane Street Group, LLC | 98,348 | $598.9K | 0.00% | +98,348 | New |
| XTX Topco Ltd | 60,061 | $365.8K | 0.00% | +60,061 | New |
| Amundi | 47,159 | $287.2K | 0.00% | +38,564+448.7% | Added |
| UBS Group AG | 43,208 | $263.1K | 0.00% | +19,323+80.9% | Added |
| Quadrature Capital Ltd | 41,750 | $254.3K | 0.00% | +41,750 | New |
| Susquehanna International Group, LLP | 23,129 | $140.9K | 0.00% | +23,129 | New |
| Squarepoint Ops LLC | 22,036 | $134.2K | 0.00% | −4,577−17.2% | Reduced |